Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study)

European Journal of Preventive Cardiology

Volumn 13, Issue 4, 2006, Pages 646-654

  Reiner, Zeljko ^a   Mihatov, Sime ^b   Miliäiä‡, Davor ^a   Bergovec, Mijo ^c   Planinc, Danijel ^b  

^a KBC Zagreb   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c University of Zagreb School of Medicine   (Croatia)

Author keywords

cardiovascular risk factors; coronary heart disease; EUROASPIRE; guidelines; secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CROATIA; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; GEOGRAPHY; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD; MEDICAL SOCIETY; PRIORITY JOURNAL; Q WAVE; REVIEW; SECONDARY PREVENTION; SEX RATIO; SMOKING; STATISTICAL SIGNIFICANCE; TRANSLUMINAL CORONARY ANGIOPLASTY; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHOLESTEROL; CORONARY DISEASE; CROATIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33746717584     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000183910.59741.96     Document Type: Article

References (31)

1. World Health Organization. The world health report 2003: shaping the future. Geneva: World Health Organization; 2003.
2. Croatian Health Service yearbook. Zagreb: Croatian National Institute of Public Health; 2004.
3. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569–1582.
4. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.
5. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–1360.
6. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898–904.
7. Wood D, De Backer G, Faegerman O, Graham I, Mancia G, Piorala K. For the Second Joint Task force of European Societies on Coronary Prevention: Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434–1503.
8. Turek S, Rudan I, Smolej-Narancic N, Szirovicza L, Cubrilo-Turek M, Zerjavic-Hrabak V, et al A large cross-sectional study of health attitudes, knowledge, behaviour and risks in the post-war Croatian population (The first Croatian Health Project). Coll Antropol 2001; 25: 77–96.
9. Reiner Z. Cardiovascular risk factors in Croatia. In: Schwandt P, Haas GM (editors): Prevention of myocardial infarction and stroke. Munich: Stiftung zur Pravention der Arteriosklerose; 2003, pp. 68–70.
10. Bergovec M, Mihatov S, Prpic H, Rogan S, Batarelo V, Sjerobabski V. Acute myocardial infarction among civilians in Zagreb city area. Lancet 1992; 339: 303.
11. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 3: 937–952.
12. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–2346.
13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423–1429.
14. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade alter myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730–1737.
15. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100000 patients in randomized trials. Circulation 1998; 97: 2202–2212.
16. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598–604.
17. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575–1581.
18. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction. Lancet 2003; 361: 1843–1848.
19. Cleland JG. Preventing atherosclerotic events with aspirin. BMJ 2002; 324: 103–105.
20. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
21. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739–745.
22. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
23. Gruppo Italiano per lo Studio della Soppravvivenza nel' infarto Miocardico. GISSI-3 effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–1122.
24. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–685.
25. Ishikawa K, Kanamasa K, Ogawa I, Takenaka T, Naito T, Kamata N, et al Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J 1996; 60: 779–788.
26. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999; 282: 2058–2067.
27. Doggrell SA. Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction. Expert Opin Pharmacother 2003; 4: 587–590.
28. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumarin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360: 109–113.
29. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535.
30. Rigotti NA, Munafo MR, Murphy MF, Stead LF. Interventions for smoking cessation in hospitalised patients (Cochrane Review). Cochrane Database Syst Rev 2003; 1: CD001837.
31. Euroaspire I and II group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995–1001.